ArticleTherapeutic advances in medical oncology2026
Prognostic performance of a novel multiplex circulating tumor DNA assay for lung cancer outcomes.
Article in Therapeutic advances in medical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung cancer is a heterogeneous disease with unpredictable trajectories. Risk stratification in lung cancer remains imprecise within tumor-node-metastasis (TNM) stages. Objectives: This work aims to evaluate whether methylated circulating tumor DNA (ctDNA) can improve prognostication at the time of diagnosis. Methods: We enrolled 213 participants with recently diagnosed lung cancer, of whom 100 underwent curative treatment and 113 underwent palliative treatment. All blood samples were collected prior to lung cancer diagnosis and analyzed using multiplex methylation-specific digital droplet polymerase chain reaction targeting five methylated ctDNA markers. ctDNA output was interpreted in two models: a three-tiered (negative/Low-level/High-level ctDNA) and a binary (negative/positive). Results: We observed significantly increased overall survival (OS) among all participants with negative or low-level ctDNA results compared with those with high-level ctDNA. The adjusted hazard ratio (HR) for OS was higher when comparing high-level ctDNA to negative results (HR = 1.96, 95% confidence interval (CI): 1.09-3.51; Conclusion: Detection of, and risk stratification based on, levels of methylated ctDNA at diagnosis appears to provide valuable prognostic information in lung cancer, both in early and late stages of the disease. Such information may have implications for the choice of follow-up regimens and treatment strategies. Design: Retrospective observational cohort study using prospectively collected blood samples.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.